Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor

Neuropharmacology

Volumn 99, Issue , 2015, Pages 301-307

  Sałat, Kinga ^a   Siwek, Agata ^a   Starowicz, Gabriela ^a   Librowski, Tadeusz ^a   Nowak, Gabriel ^a   Drabik, Urszula ^b   Gajdosz, Ryszard ^b   Popik, Piotr ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antidepressant like effects; Dehydronorketamine; Ketamine; Ketamine metabolites; NMDA receptor; Norketamine

Indexed keywords

ANTIDEPRESSANT AGENT; DEHYDRONORKETAMINE; DIZOCILPINE; ION CHANNEL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORKETAMINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; TRITIUM;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG RECEPTOR BINDING; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FORCED SWIM TEST; IMMOBILITY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; RADIOASSAY; SWIMMING;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; MICE; MOTOR ACTIVITY; RADIOLIGAND ASSAY; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING; TRITIUM;

EID: 84939794820     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.07.037     Document Type: Article

References (41)

1. J.D. Adams Jr., T.A. Baillie, A.J. Trevor, and N. Castagnoli Jr. Studies on the biotransformation of ketamine. 1-identification of metabolites produced in vitro from rat liver microsomal preparations Biomed. Mass Spectrom. 8 1981 527 538
2. N.A. Anis, S.C. Berry, N.R. Burton, and D. Lodge The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate Br. J. Pharmacol. 79 1983 565 575
3. A.J. Bechtholt, K. Smith, C.S. John, H.H. Kang, W.A. Carlezon Jr., B.M. Cohen, and D. Ongur CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy Psychopharmacology 215 2011 689 695
4. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
5. J.A. Clements, and W.S. Nimmo Pharmacokinetics and analgesic effect of ketamine in man Br. J. Anaesth. 53 1981 27 30
6. M.L. Cohen, S.L. Chan, W.L. Way, and A.J. Trevor Distribution in the brain and metabolism of ketamine in the rat after intravenous administration Anesthesiology 39 1973 370 376
7. Z. Desta, R. Moaddel, E.T. Ogburn, C. Xu, A. Ramamoorthy, S.L. Venkata, M. Sanghvi, M.E. Goldberg, M.C. Torjman, and I.W. Wainer Stereoselective and regiospecific hydroxylation of ketamine and norketamine Xenobiotica 42 2012 1076 1087
8. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 2010 793 802
9. B. Ebert, S. Mikkelsen, C. Thorkildsen, and F.M. Borgbjerg Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord Eur. J. Pharmacol. 333 1997 99 104
10. G. Fischer, V. Mutel, G. Trube, P. Malherbe, J.N. Kew, E. Mohacsi, M.P. Heitz, and J.A. Kemp Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro J. Pharmacol. Exp. Ther. 283 1997 1285 1292
11. H. Ledford Depression drug disappoints Nature 479 2011 278
12. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
13. J.F. MacDonald, Z. Miljkovic, and P. Pennefather Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine J. Neurophysiol. 58 1987 251 266
14. S. Maeng, C.A. Zarate Jr., J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol. Psychiatry 63 2008 349 352
15. J. Maj, Z. Rogoz, G. Skuza, and H. Sowinska Effects of MK-801 and antidepressant drugs in the forced swimming test in rats Eur. Neuropsychopharmacol. 2 1992 37 41
16. D. Martin, and D. Lodge Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro Neuropharmacology 24 1985 999 1003
17. R. Moaddel, G. Abdrakhmanova, J. Kozak, K. Jozwiak, L. Toll, L. Jimenez, A. Rosenberg, T. Tran, Y. Xiao, C.A. Zarate, and I.W. Wainer Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in alpha7 nicotinic acetylcholine receptors Eur. J. Pharmacol. 698 2013 228 234
18. J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, C.M. Green, A.M. Perez, S. Iqbal, S. Pillemer, A. Foulkes, A. Shah, D.S. Charney, and S.J. Mathew Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am. J. Psychiatry 170 2013 1134 1142
19. J.W. Murrough, A.M. Perez, S. Pillemer, J. Stern, M.K. Parides, R.M. aan het, K.A. Collins, S.J. Mathew, D.S. Charney, and D.V. Iosifescu Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol. Psychiatry 74 2013 250 256
20. R. Ortiz, M.J. Niciu, N. Lukkahati, L.N. Saligan, A.C. Nugent, D.A. Luckenbaugh, R. Machado-Vieira, and J. Zarate Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression J. Affect Disord. 172 2015 307 311
21. M. Papp, and E. Moryl Antidepressant activity of non-competitive NMDA antagonists in a chronic mild stress model of depression Eur. J. Pharmacol. 263 1994 1 7
22. R.K. Paul, N.S. Singh, M. Khadeer, R. Moaddel, M. Sanghvi, C.E. Green, K. O'Loughlin, M.C. Torjman, M. Bernier, and I.W. Wainer (R,S)-ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function Anesthesiology 121 2014 149 159
23. A. Pilc, J.M. Wieronska, and P. Skolnick Glutamate-based antidepressants: preclinical psychopharmacology Biol. Psychiatry 73 2013 1125 1132
24. P. Popik, T. Kos, M. Sowa-Kucma, and G. Nowak Lack of persistent effects of ketamine in rodent models of depression Psychopharmacology 198 2008 421 430
25. P. Popik, E. Kozela, and M. Krawczyk Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram Brit. J. Pharmacol. 139 2003 1196 1202
26. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 1977 327 336
27. K. Salat, K. Kulig, J. Gajda, K. Wieckowski, B. Filipek, and B. Malawska Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice Pharmacol. Biochem. Behav. 110 2013 145 153
28. M. Shimoyama, N. Shimoyama, A.L. Gorman, K.J. Elliott, and C.E. Inturrisi Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine Pain 81 1999 85 93
29. P. Skolnick Antidepressants for the new millenium Eur. J. Pharmacol. 375 1999 31 40
30. P. Skolnick, T. Kos, J. Czekaj, and P. Popik Effect of NMDA receptor antagonists in the tetrabenazine test for antidepressants: comparison to the tail suspension test Acta Neuropsychiatr. 27 2015 228 234
31. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol. Sci. 30 2009 563 569
32. K.M. Targowska-Duda, D. Feuerbach, G. Biala, K. Jozwiak, and H.R. Arias Antidepressant activity in mice elicited by 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor Neurosci. Lett. 569 2014 126 130
33. Y. Tizabi, D.H. Overstreet, A.H. Rezvani, V.A. Louis, E. Clark Jr., D.S. Janowsky, and M.A. Kling Antidepressant effects of nicotine in an animal model of depression Psychopharmacology 142 1999 193 199
34. R. Trullas, and P. Skolnick Functional antagonists at the NMDA receptor complex exhibit antidepressant actions Eur. J. Pharmacol. 185 1990 1 10
35. P.F. White, J. Schuttler, A. Shafer, D.R. Stanski, Y. Horai, and A.J. Trevor Comparative pharmacology of the ketamine isomers. Studies in volunteers Br. J. Anaesth. 57 1985 197 203
36. T.F. Woolf, and J.D. Adams Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations Xenobiotica 17 1987 839 847
37. A. Yilmaz, D. Schulz, A. Aksoy, and R. Canbeyli Prolonged effect of an anesthetic dose of ketamine on behavioral despair Pharmacol. Biochem. Behav. 71 2002 341 344
38. C.A. Zarate Jr., N. Brutsche, G. Laje, D.A. Luckenbaugh, S.L. Venkata, A. Ramamoorthy, R. Moaddel, and I.W. Wainer Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression Biol. Psychiatry 72 2012 331 338
39. C.A. Zarate, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864
40. X. Zhao, S.L.V. Venkata, R. Moaddel, D.A. Luckenbaugh, N.E. Brutsche, L. Ibrahim, C.A. Zarate, D.E. Mager, and I.W. Wainer Simultaneous population pharmacokinetic modeling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression Brit. J. Clin. Pharmacol. 74 2012 304 314
41. W. Zhou, N. Wang, C. Yang, X.M. Li, Z.Q. Zhou, and J.J. Yang Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex Eur. Psychiatry 29 2014 419 423